Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
European Journal of Cancer2018Vol. 105, pp. 41–49
Citations Over TimeTop 10% of 2018 papers
Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada, Takaaki Arigami, Akitaka Makiyama, Masaaki Iwatsuki, Yukiya Narita, Hironaga Satake, Yoshiko Matsuda, Hideto Sonoda, Mototsugu Shimokawa, Yoshihiko Maehara
Related Papers
- → Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients(2020)5 cited
- → A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK(2001)3 cited
- → Advanced research on neoadjuvant therapy with trastuzumab in HER2-positive breast cancer(2014)
- Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis(2019)